Brian A. Teras

• Represented e-commerce company in its sale to a publicly-traded company for $240 million in cash and stock

Represented publicly-traded biotech company in numerous license, asset purchase and divestiture transactions

Represented medical device company in the following transactions for aggregate consideration of $35 million:

• – Strategic investment transaction to sell 20% of the company to a publicly traded medical device company and grant of purchase option for the remaining 80% of the company
• – Negotiation and closing of the acquirer’s subsequent exercise of the purchase option

Represented a publicly traded healthcare IT company in the following:

• – Initial public offering (IPO) and NYSE listing
• – $640 million sale of the company to a large private equity firm

Represented a publicly traded healthcare services provider in the following:

• – $100 million registered secondary offering of common stock
• – $75 million acquisition of a specialty healthcare company and other roll-up acquisitions
• – $250 million Rule 144A senior notes offering

Represented private equity-backed buyer in several medical practice acquisitions

Represented biopharmaceutical company in $20 million Series B preferred stock financing

Represented contract research organization (CRO) in $150 million sale to publicly traded contract research services firm

Represented real estate development company in $20 million Rule 506(c) “general solicitation” equity offering

Represented European-based venture capital firm in early-stage investments in several U.S. life sciences companies

Represented healthcare private equity firm in its acquisition of a medical device manufacturer

Represented a publicly traded life sciences company in acquisition of an add-on regenerative medicine company

Represented a transportation company in the following:

• – Dividend recap and issuance of $150 million of senior notes
• – $225 million Rule 144A senior secured notes offering and related tender offer for existing debt $150 million acquisition financing (Rule 144A secured notes offering)
• – Private placement of approximately $70 million of secured notes and preferred stock

Represented a national homebuilder in the following:

• – $300 million Rule 144A senior notes offering
• – $50 million Rule 144A tack-on notes offering

Represented a casino and gaming company in Rule 144A $100 million senior notes offering

Represented a manufacturing company in its $30 million sale to private equity firm

Represented a private investment firm in the acquisition of multiple machine lubrication businesses

Represented an investor group in connection with the acquisition of a minority interest in a national sports franchise

Represented a private equity fund in the acquisition of an automotive chemicals company

Represented an environmental services company in several roll-up acquisitions

Represented U.S. pharmaceutical company in its sale of substantially all of the assets of a business division. The sale consisted of a portfolio of mature products.